“Purple Book” Patent Listing Under Biological Product Patent Transparency Act: What is Required, and What to Expect?

Published date08 April 2021
Subject MatterFTC,FDA,Transparency,Patent Trial and Appeal Board,BPCIA,Purple Book,Orange Book,Antitrust Violations,aBLA,Abbreviated New Drug Application (ANDA),Consolidated Appropriations Act (CAA)
AuthorChristina Markus,Vanessa Yen,Evan Diamond,Eva Temkin
Law FirmKing & Spalding

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT